Mallinckrodt licenses Metasyn MRI agent

Article

MRI contrast-agent developer Metasyn of Cambridge, MA, has landeda product development and licensing deal with Mallinckrodt Medicalof St. Louis for Metasyn's MS-325 gadolinium-based agent for MRangiography of coronary and peripheral arteries. The deal

MRI contrast-agent developer Metasyn of Cambridge, MA, has landeda product development and licensing deal with Mallinckrodt Medicalof St. Louis for Metasyn's MS-325 gadolinium-based agent for MRangiography of coronary and peripheral arteries. The deal alsoincludes other MRI vascular agents that may be developed by thecompanies.

Metasyn is beginning phase I clinical trials for MS-325, whichit hopes will replace other modalities, such as x-ray angiography,in cardiac assessment studies (SCAN 7/31/96). Mallinckrodt willmake an up-front $6 million licensing fee as part of the deal.

Mallinckrodt gains sales and marketing rights for MS-325 inall parts of the world except Japan. Metasyn granted licensingrights in that nation to Daiichi Pharmaceutical in April.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.